CORONAVIRUS INFECTIOUS DISEASE COVID-19 THERAPEUTIC PROTEINS CTP ALPHA, CTP BETA, CTP GAMMA, CTP DELTA, AND USES THEREOF

The present invention relates to coronavirus infectious disease COVID-19 therapeutic proteins CTP alpha, CTP beta, CTP gamma, CTP delta, and uses thereof. Compared to a known peptide (P6) which mimics the binding site of a receptor binding domain (RBD) of SARS-CoV and angiotensin-converting enzyme 2...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	KIM, Min Gi, LEE, Ae Ree, MIN, Ga Hee, KANG, Mooseok, JI, Sang Ho, CHOI, Min Jee, KIM, Sang Yeol, LEE, Young-Ho, CHOI, Jae Seok, CHOI, Seong Kyoon, KIM, Hee Yeon, KIM, Hyo Eun, CHANG, Iksoo, LEE, Juhwan, PARK, Song, KWON, Wookbong, YU, Woo Kyung, PARK, Seongjun, SEO, Souk, LEE, Kyung Eun
Format:	Patent
Sprache:	eng ; fre ; kor
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FOODS OR FOODSTUFFS FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS TESTING THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT THEIR TREATMENT, NOT COVERED BY OTHER CLASSES VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	KIM, Min Gi LEE, Ae Ree MIN, Ga Hee KANG, Mooseok JI, Sang Ho CHOI, Min Jee KIM, Sang Yeol LEE, Young-Ho CHOI, Jae Seok CHOI, Seong Kyoon KIM, Hee Yeon KIM, Hyo Eun CHANG, Iksoo LEE, Juhwan PARK, Song KWON, Wookbong YU, Woo Kyung PARK, Seongjun SEO, Souk LEE, Kyung Eun
description	The present invention relates to coronavirus infectious disease COVID-19 therapeutic proteins CTP alpha, CTP beta, CTP gamma, CTP delta, and uses thereof. Compared to a known peptide (P6) which mimics the binding site of a receptor binding domain (RBD) of SARS-CoV and angiotensin-converting enzyme 2 (ACE2), the therapeutic proteins CTP alpha, CTP beta, CTP gamma, and CTP delta according to the present invention comprise a novel part obtained by adding a novel sequence of amino acids, wherein the interaction of atoms constituting the amino acids has been fundamentally designed in order to strengthen the binding of SARS-CoV2 to a novel epitope of RBD. The present invention provides therapeutic proteins CTP alpha, CTP beta, CTP gamma, and CTP delta having a novel design and capable of binding more strongly than known peptides due to being creative designs of the extended therapeutic proteins CTP alpha, CTP beta, CTP gamma, and CTP delta, wherein the therapeutic proteins can additionally interact with charged amino acids of D420 and K458 on the rear side of the conventional binding interface between RBD and hACE2 or additionally interact with charged amino acids such as R454, K458, D467, and E471. The therapeutic proteins CTP alpha, CTP beta, CTP gamma, and CTP delta according to the present invention have the potential of being highly applicable as COVID-19 therapeutic agents. La présente invention concerne des protéines thérapeutiques CTP alpha, CTP bêta, CTP gamma, CTP delta pour maladie infectieuse du coronavirus COVID-19 et leurs utilisations. Par comparaison avec un peptide connu (P6) qui imite le site de liaison d'un domaine de liaison au récepteur (RBD) du SARS-CoV et de l'enzyme de conversion de l'angiotensine 2 (ACE2), les protéines thérapeutiques CTP alpha, CTP bêta, CTP gamma et CTP delta selon la présente invention comprennent une nouvelle partie obtenue par ajout d'une nouvelle séquence d'acides aminés, l'interaction des atomes constituant les acides aminés ayant été fondamentalement conçue pour renforcer la liaison du SARS-CoV2 à un nouvel épitope de RBD. La présente invention concerne des protéines thérapeutiques CTP alpha, CTP bêta, CTP gamma et CTP delta ayant une nouvelle conception et pouvant se lier plus fortement que les peptides connus en raison des conceptions créatives des protéines thérapeutiques étendues CTP alpha, CTP bêta, CTP gamma et CTP delta, les protéines thérapeutiques pouvant en outre interagir avec des acides aminés chargés
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2022108013A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2022108013A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2022108013A13</originalsourceid><addsrcrecordid>eNqNzLEKwjAUBdAuDqL-wwNXC01ddHwmrzbQJiF5rWMpEifRQh38fLX0A5zu4XK5y-QtrbcGW-2bANoUJFnbL5UOhIFA2larVByBS_LoqGEtwXnLpE0AyQ6wciXuJp6IZ52xrmcqqn4tGgVNoDAdkS3WyeLW38e4mXOVbAtiWaZxeHZxHPprfMRXd7F5luciO2Rij2L_3-oDKxI6AA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>CORONAVIRUS INFECTIOUS DISEASE COVID-19 THERAPEUTIC PROTEINS CTP ALPHA, CTP BETA, CTP GAMMA, CTP DELTA, AND USES THEREOF</title><source>esp@cenet</source><creator>KIM, Min Gi ; LEE, Ae Ree ; MIN, Ga Hee ; KANG, Mooseok ; JI, Sang Ho ; CHOI, Min Jee ; KIM, Sang Yeol ; LEE, Young-Ho ; CHOI, Jae Seok ; CHOI, Seong Kyoon ; KIM, Hee Yeon ; KIM, Hyo Eun ; CHANG, Iksoo ; LEE, Juhwan ; PARK, Song ; KWON, Wookbong ; YU, Woo Kyung ; PARK, Seongjun ; SEO, Souk ; LEE, Kyung Eun</creator><creatorcontrib>KIM, Min Gi ; LEE, Ae Ree ; MIN, Ga Hee ; KANG, Mooseok ; JI, Sang Ho ; CHOI, Min Jee ; KIM, Sang Yeol ; LEE, Young-Ho ; CHOI, Jae Seok ; CHOI, Seong Kyoon ; KIM, Hee Yeon ; KIM, Hyo Eun ; CHANG, Iksoo ; LEE, Juhwan ; PARK, Song ; KWON, Wookbong ; YU, Woo Kyung ; PARK, Seongjun ; SEO, Souk ; LEE, Kyung Eun</creatorcontrib><description>The present invention relates to coronavirus infectious disease COVID-19 therapeutic proteins CTP alpha, CTP beta, CTP gamma, CTP delta, and uses thereof. Compared to a known peptide (P6) which mimics the binding site of a receptor binding domain (RBD) of SARS-CoV and angiotensin-converting enzyme 2 (ACE2), the therapeutic proteins CTP alpha, CTP beta, CTP gamma, and CTP delta according to the present invention comprise a novel part obtained by adding a novel sequence of amino acids, wherein the interaction of atoms constituting the amino acids has been fundamentally designed in order to strengthen the binding of SARS-CoV2 to a novel epitope of RBD. The present invention provides therapeutic proteins CTP alpha, CTP beta, CTP gamma, and CTP delta having a novel design and capable of binding more strongly than known peptides due to being creative designs of the extended therapeutic proteins CTP alpha, CTP beta, CTP gamma, and CTP delta, wherein the therapeutic proteins can additionally interact with charged amino acids of D420 and K458 on the rear side of the conventional binding interface between RBD and hACE2 or additionally interact with charged amino acids such as R454, K458, D467, and E471. The therapeutic proteins CTP alpha, CTP beta, CTP gamma, and CTP delta according to the present invention have the potential of being highly applicable as COVID-19 therapeutic agents. La présente invention concerne des protéines thérapeutiques CTP alpha, CTP bêta, CTP gamma, CTP delta pour maladie infectieuse du coronavirus COVID-19 et leurs utilisations. Par comparaison avec un peptide connu (P6) qui imite le site de liaison d'un domaine de liaison au récepteur (RBD) du SARS-CoV et de l'enzyme de conversion de l'angiotensine 2 (ACE2), les protéines thérapeutiques CTP alpha, CTP bêta, CTP gamma et CTP delta selon la présente invention comprennent une nouvelle partie obtenue par ajout d'une nouvelle séquence d'acides aminés, l'interaction des atomes constituant les acides aminés ayant été fondamentalement conçue pour renforcer la liaison du SARS-CoV2 à un nouvel épitope de RBD. La présente invention concerne des protéines thérapeutiques CTP alpha, CTP bêta, CTP gamma et CTP delta ayant une nouvelle conception et pouvant se lier plus fortement que les peptides connus en raison des conceptions créatives des protéines thérapeutiques étendues CTP alpha, CTP bêta, CTP gamma et CTP delta, les protéines thérapeutiques pouvant en outre interagir avec des acides aminés chargés de D420 et K458 sur le côté arrière de l'interface de liaison classique entre RBD et hACE2 ou en outre interagir avec des acides aminés chargés tels que R454, K458, D467 et E471. Les protéines thérapeutiques CTP alpha, CTP bêta, CTP gamma et CTP delta selon la présente invention ont le potentiel d'être hautement utiles en tant qu'agents thérapeutiques contre la COVID-19. 본 발명은 코로나바이러스 감염증 COVID-19 치료제 단백질 CTP 알파, CTP 베타, CTP 감마, CTP 델타 및 이의 용도에 관한 것으로서, 기존에 알려진 SARS-CoV의 RBD와 ACE2의 결합부위를 모사하는 펩타이드(P6)에 비해, 본 발명의 치료제 단백질 CTP 알파, CTP 베타, CTP 감마, CTP 델타는 SARS-CoV2 RBD의 새로운 에피토프와의 결합을 더욱 강하게 만들기 위해 아미노산을 구성하는 원자들 차원의 상호작용을 원천적으로 디자인한, 아미노산의 새로운 서열을 추가한 새로운 부분으로 구성되어 있다. 본 발명에서는, RBD와 hACE2 사이의 기존에 알려진 결합 경계면의 후면에 있는 D420, K458의 전하를 띄는(Charged) 아미노산들과 추가적으로 상호작용하거나, R454, K458, D467, E471 등의 전하를 띄는(Charged) 아미노산들과 추가적으로 상호작용할 수 있는, 확장된 치료제 단백질 CTP 알파, CTP 베타, CTP 감마, CTP 델타를 독창적으로 디자인하여 기존 알려진 펩타이드 보다 강하게 결합할 수 있는 새로운 디자인의 치료제 단백질 CTP 알파, CTP 베타, CTP 감마, CTP 델타를 제시하였으며, 본 발명의 치료제 단백질 CTP 알파, CTP 베타, CTP 감마, CTP 델타는 향후 COVID-19 치료제로서 높은 활용 가능성을 나타낸다.</description><language>eng ; fre ; kor</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; FOODS OR FOODSTUFFS ; FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J ; HUMAN NECESSITIES ; HYGIENE ; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES ; MEASURING ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PHYSICS ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; TESTING ; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT ; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES ; VINEGAR ; WINE</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220527&DB=EPODOC&CC=WO&NR=2022108013A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220527&DB=EPODOC&CC=WO&NR=2022108013A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>KIM, Min Gi</creatorcontrib><creatorcontrib>LEE, Ae Ree</creatorcontrib><creatorcontrib>MIN, Ga Hee</creatorcontrib><creatorcontrib>KANG, Mooseok</creatorcontrib><creatorcontrib>JI, Sang Ho</creatorcontrib><creatorcontrib>CHOI, Min Jee</creatorcontrib><creatorcontrib>KIM, Sang Yeol</creatorcontrib><creatorcontrib>LEE, Young-Ho</creatorcontrib><creatorcontrib>CHOI, Jae Seok</creatorcontrib><creatorcontrib>CHOI, Seong Kyoon</creatorcontrib><creatorcontrib>KIM, Hee Yeon</creatorcontrib><creatorcontrib>KIM, Hyo Eun</creatorcontrib><creatorcontrib>CHANG, Iksoo</creatorcontrib><creatorcontrib>LEE, Juhwan</creatorcontrib><creatorcontrib>PARK, Song</creatorcontrib><creatorcontrib>KWON, Wookbong</creatorcontrib><creatorcontrib>YU, Woo Kyung</creatorcontrib><creatorcontrib>PARK, Seongjun</creatorcontrib><creatorcontrib>SEO, Souk</creatorcontrib><creatorcontrib>LEE, Kyung Eun</creatorcontrib><title>CORONAVIRUS INFECTIOUS DISEASE COVID-19 THERAPEUTIC PROTEINS CTP ALPHA, CTP BETA, CTP GAMMA, CTP DELTA, AND USES THEREOF</title><description>The present invention relates to coronavirus infectious disease COVID-19 therapeutic proteins CTP alpha, CTP beta, CTP gamma, CTP delta, and uses thereof. Compared to a known peptide (P6) which mimics the binding site of a receptor binding domain (RBD) of SARS-CoV and angiotensin-converting enzyme 2 (ACE2), the therapeutic proteins CTP alpha, CTP beta, CTP gamma, and CTP delta according to the present invention comprise a novel part obtained by adding a novel sequence of amino acids, wherein the interaction of atoms constituting the amino acids has been fundamentally designed in order to strengthen the binding of SARS-CoV2 to a novel epitope of RBD. The present invention provides therapeutic proteins CTP alpha, CTP beta, CTP gamma, and CTP delta having a novel design and capable of binding more strongly than known peptides due to being creative designs of the extended therapeutic proteins CTP alpha, CTP beta, CTP gamma, and CTP delta, wherein the therapeutic proteins can additionally interact with charged amino acids of D420 and K458 on the rear side of the conventional binding interface between RBD and hACE2 or additionally interact with charged amino acids such as R454, K458, D467, and E471. The therapeutic proteins CTP alpha, CTP beta, CTP gamma, and CTP delta according to the present invention have the potential of being highly applicable as COVID-19 therapeutic agents. La présente invention concerne des protéines thérapeutiques CTP alpha, CTP bêta, CTP gamma, CTP delta pour maladie infectieuse du coronavirus COVID-19 et leurs utilisations. Par comparaison avec un peptide connu (P6) qui imite le site de liaison d'un domaine de liaison au récepteur (RBD) du SARS-CoV et de l'enzyme de conversion de l'angiotensine 2 (ACE2), les protéines thérapeutiques CTP alpha, CTP bêta, CTP gamma et CTP delta selon la présente invention comprennent une nouvelle partie obtenue par ajout d'une nouvelle séquence d'acides aminés, l'interaction des atomes constituant les acides aminés ayant été fondamentalement conçue pour renforcer la liaison du SARS-CoV2 à un nouvel épitope de RBD. La présente invention concerne des protéines thérapeutiques CTP alpha, CTP bêta, CTP gamma et CTP delta ayant une nouvelle conception et pouvant se lier plus fortement que les peptides connus en raison des conceptions créatives des protéines thérapeutiques étendues CTP alpha, CTP bêta, CTP gamma et CTP delta, les protéines thérapeutiques pouvant en outre interagir avec des acides aminés chargés de D420 et K458 sur le côté arrière de l'interface de liaison classique entre RBD et hACE2 ou en outre interagir avec des acides aminés chargés tels que R454, K458, D467 et E471. Les protéines thérapeutiques CTP alpha, CTP bêta, CTP gamma et CTP delta selon la présente invention ont le potentiel d'être hautement utiles en tant qu'agents thérapeutiques contre la COVID-19. 본 발명은 코로나바이러스 감염증 COVID-19 치료제 단백질 CTP 알파, CTP 베타, CTP 감마, CTP 델타 및 이의 용도에 관한 것으로서, 기존에 알려진 SARS-CoV의 RBD와 ACE2의 결합부위를 모사하는 펩타이드(P6)에 비해, 본 발명의 치료제 단백질 CTP 알파, CTP 베타, CTP 감마, CTP 델타는 SARS-CoV2 RBD의 새로운 에피토프와의 결합을 더욱 강하게 만들기 위해 아미노산을 구성하는 원자들 차원의 상호작용을 원천적으로 디자인한, 아미노산의 새로운 서열을 추가한 새로운 부분으로 구성되어 있다. 본 발명에서는, RBD와 hACE2 사이의 기존에 알려진 결합 경계면의 후면에 있는 D420, K458의 전하를 띄는(Charged) 아미노산들과 추가적으로 상호작용하거나, R454, K458, D467, E471 등의 전하를 띄는(Charged) 아미노산들과 추가적으로 상호작용할 수 있는, 확장된 치료제 단백질 CTP 알파, CTP 베타, CTP 감마, CTP 델타를 독창적으로 디자인하여 기존 알려진 펩타이드 보다 강하게 결합할 수 있는 새로운 디자인의 치료제 단백질 CTP 알파, CTP 베타, CTP 감마, CTP 델타를 제시하였으며, 본 발명의 치료제 단백질 CTP 알파, CTP 베타, CTP 감마, CTP 델타는 향후 COVID-19 치료제로서 높은 활용 가능성을 나타낸다.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>FOODS OR FOODSTUFFS</subject><subject>FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</subject><subject>MEASURING</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PHYSICS</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>TESTING</subject><subject>THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT</subject><subject>THEIR TREATMENT, NOT COVERED BY OTHER CLASSES</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNzLEKwjAUBdAuDqL-wwNXC01ddHwmrzbQJiF5rWMpEifRQh38fLX0A5zu4XK5y-QtrbcGW-2bANoUJFnbL5UOhIFA2larVByBS_LoqGEtwXnLpE0AyQ6wciXuJp6IZ52xrmcqqn4tGgVNoDAdkS3WyeLW38e4mXOVbAtiWaZxeHZxHPprfMRXd7F5luciO2Rij2L_3-oDKxI6AA</recordid><startdate>20220527</startdate><enddate>20220527</enddate><creator>KIM, Min Gi</creator><creator>LEE, Ae Ree</creator><creator>MIN, Ga Hee</creator><creator>KANG, Mooseok</creator><creator>JI, Sang Ho</creator><creator>CHOI, Min Jee</creator><creator>KIM, Sang Yeol</creator><creator>LEE, Young-Ho</creator><creator>CHOI, Jae Seok</creator><creator>CHOI, Seong Kyoon</creator><creator>KIM, Hee Yeon</creator><creator>KIM, Hyo Eun</creator><creator>CHANG, Iksoo</creator><creator>LEE, Juhwan</creator><creator>PARK, Song</creator><creator>KWON, Wookbong</creator><creator>YU, Woo Kyung</creator><creator>PARK, Seongjun</creator><creator>SEO, Souk</creator><creator>LEE, Kyung Eun</creator><scope>EVB</scope></search><sort><creationdate>20220527</creationdate><title>CORONAVIRUS INFECTIOUS DISEASE COVID-19 THERAPEUTIC PROTEINS CTP ALPHA, CTP BETA, CTP GAMMA, CTP DELTA, AND USES THEREOF</title><author>KIM, Min Gi ; LEE, Ae Ree ; MIN, Ga Hee ; KANG, Mooseok ; JI, Sang Ho ; CHOI, Min Jee ; KIM, Sang Yeol ; LEE, Young-Ho ; CHOI, Jae Seok ; CHOI, Seong Kyoon ; KIM, Hee Yeon ; KIM, Hyo Eun ; CHANG, Iksoo ; LEE, Juhwan ; PARK, Song ; KWON, Wookbong ; YU, Woo Kyung ; PARK, Seongjun ; SEO, Souk ; LEE, Kyung Eun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2022108013A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; kor</language><creationdate>2022</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>FOODS OR FOODSTUFFS</topic><topic>FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</topic><topic>MEASURING</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PHYSICS</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>TESTING</topic><topic>THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT</topic><topic>THEIR TREATMENT, NOT COVERED BY OTHER CLASSES</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>KIM, Min Gi</creatorcontrib><creatorcontrib>LEE, Ae Ree</creatorcontrib><creatorcontrib>MIN, Ga Hee</creatorcontrib><creatorcontrib>KANG, Mooseok</creatorcontrib><creatorcontrib>JI, Sang Ho</creatorcontrib><creatorcontrib>CHOI, Min Jee</creatorcontrib><creatorcontrib>KIM, Sang Yeol</creatorcontrib><creatorcontrib>LEE, Young-Ho</creatorcontrib><creatorcontrib>CHOI, Jae Seok</creatorcontrib><creatorcontrib>CHOI, Seong Kyoon</creatorcontrib><creatorcontrib>KIM, Hee Yeon</creatorcontrib><creatorcontrib>KIM, Hyo Eun</creatorcontrib><creatorcontrib>CHANG, Iksoo</creatorcontrib><creatorcontrib>LEE, Juhwan</creatorcontrib><creatorcontrib>PARK, Song</creatorcontrib><creatorcontrib>KWON, Wookbong</creatorcontrib><creatorcontrib>YU, Woo Kyung</creatorcontrib><creatorcontrib>PARK, Seongjun</creatorcontrib><creatorcontrib>SEO, Souk</creatorcontrib><creatorcontrib>LEE, Kyung Eun</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>KIM, Min Gi</au><au>LEE, Ae Ree</au><au>MIN, Ga Hee</au><au>KANG, Mooseok</au><au>JI, Sang Ho</au><au>CHOI, Min Jee</au><au>KIM, Sang Yeol</au><au>LEE, Young-Ho</au><au>CHOI, Jae Seok</au><au>CHOI, Seong Kyoon</au><au>KIM, Hee Yeon</au><au>KIM, Hyo Eun</au><au>CHANG, Iksoo</au><au>LEE, Juhwan</au><au>PARK, Song</au><au>KWON, Wookbong</au><au>YU, Woo Kyung</au><au>PARK, Seongjun</au><au>SEO, Souk</au><au>LEE, Kyung Eun</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>CORONAVIRUS INFECTIOUS DISEASE COVID-19 THERAPEUTIC PROTEINS CTP ALPHA, CTP BETA, CTP GAMMA, CTP DELTA, AND USES THEREOF</title><date>2022-05-27</date><risdate>2022</risdate><abstract>The present invention relates to coronavirus infectious disease COVID-19 therapeutic proteins CTP alpha, CTP beta, CTP gamma, CTP delta, and uses thereof. Compared to a known peptide (P6) which mimics the binding site of a receptor binding domain (RBD) of SARS-CoV and angiotensin-converting enzyme 2 (ACE2), the therapeutic proteins CTP alpha, CTP beta, CTP gamma, and CTP delta according to the present invention comprise a novel part obtained by adding a novel sequence of amino acids, wherein the interaction of atoms constituting the amino acids has been fundamentally designed in order to strengthen the binding of SARS-CoV2 to a novel epitope of RBD. The present invention provides therapeutic proteins CTP alpha, CTP beta, CTP gamma, and CTP delta having a novel design and capable of binding more strongly than known peptides due to being creative designs of the extended therapeutic proteins CTP alpha, CTP beta, CTP gamma, and CTP delta, wherein the therapeutic proteins can additionally interact with charged amino acids of D420 and K458 on the rear side of the conventional binding interface between RBD and hACE2 or additionally interact with charged amino acids such as R454, K458, D467, and E471. The therapeutic proteins CTP alpha, CTP beta, CTP gamma, and CTP delta according to the present invention have the potential of being highly applicable as COVID-19 therapeutic agents. La présente invention concerne des protéines thérapeutiques CTP alpha, CTP bêta, CTP gamma, CTP delta pour maladie infectieuse du coronavirus COVID-19 et leurs utilisations. Par comparaison avec un peptide connu (P6) qui imite le site de liaison d'un domaine de liaison au récepteur (RBD) du SARS-CoV et de l'enzyme de conversion de l'angiotensine 2 (ACE2), les protéines thérapeutiques CTP alpha, CTP bêta, CTP gamma et CTP delta selon la présente invention comprennent une nouvelle partie obtenue par ajout d'une nouvelle séquence d'acides aminés, l'interaction des atomes constituant les acides aminés ayant été fondamentalement conçue pour renforcer la liaison du SARS-CoV2 à un nouvel épitope de RBD. La présente invention concerne des protéines thérapeutiques CTP alpha, CTP bêta, CTP gamma et CTP delta ayant une nouvelle conception et pouvant se lier plus fortement que les peptides connus en raison des conceptions créatives des protéines thérapeutiques étendues CTP alpha, CTP bêta, CTP gamma et CTP delta, les protéines thérapeutiques pouvant en outre interagir avec des acides aminés chargés de D420 et K458 sur le côté arrière de l'interface de liaison classique entre RBD et hACE2 ou en outre interagir avec des acides aminés chargés tels que R454, K458, D467 et E471. Les protéines thérapeutiques CTP alpha, CTP bêta, CTP gamma et CTP delta selon la présente invention ont le potentiel d'être hautement utiles en tant qu'agents thérapeutiques contre la COVID-19. 본 발명은 코로나바이러스 감염증 COVID-19 치료제 단백질 CTP 알파, CTP 베타, CTP 감마, CTP 델타 및 이의 용도에 관한 것으로서, 기존에 알려진 SARS-CoV의 RBD와 ACE2의 결합부위를 모사하는 펩타이드(P6)에 비해, 본 발명의 치료제 단백질 CTP 알파, CTP 베타, CTP 감마, CTP 델타는 SARS-CoV2 RBD의 새로운 에피토프와의 결합을 더욱 강하게 만들기 위해 아미노산을 구성하는 원자들 차원의 상호작용을 원천적으로 디자인한, 아미노산의 새로운 서열을 추가한 새로운 부분으로 구성되어 있다. 본 발명에서는, RBD와 hACE2 사이의 기존에 알려진 결합 경계면의 후면에 있는 D420, K458의 전하를 띄는(Charged) 아미노산들과 추가적으로 상호작용하거나, R454, K458, D467, E471 등의 전하를 띄는(Charged) 아미노산들과 추가적으로 상호작용할 수 있는, 확장된 치료제 단백질 CTP 알파, CTP 베타, CTP 감마, CTP 델타를 독창적으로 디자인하여 기존 알려진 펩타이드 보다 강하게 결합할 수 있는 새로운 디자인의 치료제 단백질 CTP 알파, CTP 베타, CTP 감마, CTP 델타를 제시하였으며, 본 발명의 치료제 단백질 CTP 알파, CTP 베타, CTP 감마, CTP 델타는 향후 COVID-19 치료제로서 높은 활용 가능성을 나타낸다.</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	eng ; fre ; kor
recordid	cdi_epo_espacenet_WO2022108013A1
source	esp@cenet
subjects	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FOODS OR FOODSTUFFS FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS TESTING THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT THEIR TREATMENT, NOT COVERED BY OTHER CLASSES VINEGAR WINE
title	CORONAVIRUS INFECTIOUS DISEASE COVID-19 THERAPEUTIC PROTEINS CTP ALPHA, CTP BETA, CTP GAMMA, CTP DELTA, AND USES THEREOF
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T09%3A21%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=KIM,%20Min%20Gi&rft.date=2022-05-27&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2022108013A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true